Herbert Ira Hurwitz, MD

Adjunct Professor in the Department of Medicine
Campus mail 439 Seeley-Mudd Bldg, 10 Bryan Searle Drive, Duke University M, Durham, NC 27710
Phone (919) 681-6006
Email address hurwi004@mc.duke.edu

Particular Clinical Interests and Skills: Phase I clinical trials involving new anti cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system

Education and Training

  • Clinical Oncology Fellow, Medicine, Johns Hopkins University, 1992 - 1996
  • Medical Resident, Medicine, Michael Reese Hospital & Medical Center, 1988 - 1991
  • M.D., Thomas Jefferson University, 1988

Publications

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)..” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.

PMID
31444620
Full Text

Burzykowski, Tomasz, Elisabeth Coart, Everardo D. Saad, Qian Shi, Dirkje W. Sommeijer, Carsten Bokemeyer, Eduardo Díaz-Rubio, et al. “Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer..” Jama Netw Open 2, no. 9 (September 4, 2019). https://doi.org/10.1001/jamanetworkopen.2019.11750.

PMID
31539075
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)..” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.

PMID
30889042
Full Text

Coker, Shodeinde A., Herbert I. Hurwitz, Sunil Sharma, Ding Wang, Pierre Jordaan, Juan Pablo Zarate, and Lionel D. Lewis. “The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors..” Cancer Chemother Pharmacol 84, no. 2 (August 2019): 383–92. https://doi.org/10.1007/s00280-019-03880-9.

PMID
31187169
Full Text

Hurwitz, Herbert I., Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz-Josef Lenz, Howard S. Hochster, et al. “Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)..” Oncologist 24, no. 7 (July 2019): 921–32. https://doi.org/10.1634/theoncologist.2018-0344.

PMID
30552157
Full Text

Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors..” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.

PMID
30895346
Full Text

Meric-Bernstam, Funda, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R. McWilliams, Marwan Fakih, Ari VanderWalde, Charles Swanton, et al. “Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study..” Lancet Oncol 20, no. 4 (April 2019): 518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.

PMID
30857956
Full Text

Loupakis, Fotios, Herbert I. Hurwitz, Leonard Saltz, Dirk Arnold, Axel Grothey, Quynh Lan Nguyen, Stuart Osborne, Jonathan Talbot, Stefanie Srock, and Heinz-Josef Lenz. “Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer..” Br J Cancer 119, no. 12 (December 2018): 1451–55. https://doi.org/10.1038/s41416-018-0304-6.

PMID
30487637
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients..” Sci Rep 8, no. 1 (November 5, 2018). https://doi.org/10.1038/s41598-018-34506-4.

PMID
30397360
Full Text

Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105..” Mol Cancer Ther 17, no. 10 (October 2018): 2248–56. https://doi.org/10.1158/1535-7163.MCT-17-0916.

PMID
29997150
Full Text

Pages